Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Brandão M, Martins-Branco D, De Angelis C, Vuylsteke P, Gelber RD, Van Damme N, van Walle L, Ferreira AR, Lambertini M, Poggio F, Verhoeven D, Barbeaux A, Duhoux FP, Wildiers H, Caballero C, Awada A, Piccart-Gebhart M, Punie K, de Azambuja E. Brandão M, et al. Among authors: ferreira ar. Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07275-0. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38592543 No abstract available.
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Brandão M, Martins-Branco D, De Angelis C, Vuylsteke P, Gelber RD, Van Damme N, van Walle L, Ferreira AR, Lambertini M, Poggio F, Verhoeven D, Barbeaux A, Duhoux FP, Wildiers H, Caballero C, Awada A, Piccart-Gebhart M, Punie K, de Azambuja E. Brandão M, et al. Among authors: ferreira ar. Breast Cancer Res Treat. 2024 Jan;203(2):351-363. doi: 10.1007/s10549-023-07116-6. Epub 2023 Oct 25. Breast Cancer Res Treat. 2024. PMID: 37878152
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E. Lambertini M, et al. Among authors: ferreira ar. Breast Cancer Res Treat. 2019 Aug;177(1):103-114. doi: 10.1007/s10549-019-05284-y. Epub 2019 May 27. Breast Cancer Res Treat. 2019. PMID: 31134488 Clinical Trial.
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L. Lambertini M, et al. Among authors: ferreira ar. Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11. Clin Breast Cancer. 2017. PMID: 28479052
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Martel S, Bruzzone M, Ceppi M, Maurer C, Ponde NF, Ferreira AR, Viglietti G, Del Mastro L, Prady C, de Azambuja E, Lambertini M. Martel S, et al. Among authors: ferreira ar. Cancer Treat Rev. 2018 Jan;62:123-132. doi: 10.1016/j.ctrv.2017.09.009. Epub 2017 Nov 3. Cancer Treat Rev. 2018. PMID: 29108713 Review.
Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants.
Lambertini M, Ceppi M, Hamy AS, Caron O, Poorvu PD, Carrasco E, Grinshpun A, Punie K, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Toss A, Senechal C, Puglisi F, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Duhoux FP, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Ferreira AR, Partridge AH, Di Meglio A, Saule C, Peccatori FA, Bruzzone M, t'Kint de Roodenbeke MD, Ameye L, Balmaña J, Del Mastro L, Azim HA Jr. Lambertini M, et al. Among authors: ferreira ar. NPJ Breast Cancer. 2021 Feb 12;7(1):16. doi: 10.1038/s41523-021-00224-w. NPJ Breast Cancer. 2021. PMID: 33579978 Free PMC article.
Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice.
Alves da Costa F, Cardoso Borges F, Ramos A, Mayer A, Brito C, Ramos C, Bernardo C, Cossito M, Furtado C, Ferreira AR, Martins-Branco D, da Costa Miranda A, Lourenço A. Alves da Costa F, et al. Among authors: ferreira ar. Breast Cancer Res. 2023 Jun 29;25(1):78. doi: 10.1186/s13058-023-01678-5. Breast Cancer Res. 2023. PMID: 37386484 Free PMC article.
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Lambertini M, et al. JAMA. 2024 Jan 2;331(1):49-59. doi: 10.1001/jama.2023.25463. JAMA. 2024. PMID: 38059899
246 results